Revlimid® (lenalidomide) – Expanded indication
February 22, 2017 – The FDA approved Celgene’s Revlimid (lenalidomide) for multiple myeloma (MM), as maintenance treatment following autologous hematopoietic stem cell transplantation (auto-HSCT).
Download PDF
